<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:37:06Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/27650" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/27650</identifier><datestamp>2026-09-24T02:04:04Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Schertzer, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Singh, Anita</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-06-21T20:32:46Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-06-21T20:32:46Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/27650</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/21626</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Obesity-induced inflammation is a factor involved in the risk and progression of type 2 diabetes and non-alcoholic fatty liver disease. These diseases are associated with changes in gut microbiota composition and bacterial metabolites. Bacterial components with known innate immune receptors can cooperate with non-immunogenic metabolites derived from the gut microbiota to alter host immunity. Gut bacteria produce almost all D-lactate in the host, whereas L-lactate is host-derived. It is known that microbial-derived D-lactate in the portal circulation programs liver-resident macrophages to help combat bacterial infections. It was unknown how D-lactate and L-lactate alter cell-autonomous inflammation in macrophages exposed to low levels of bacterial cell wall muropeptides or lipopolysaccharide (LPS). It was also unknown if macrophage co-stimulation altered inflammation in macrophages exposed to bacterial metabolites and cell wall components. In vitro models showed that D-lactate had no effect (or a very small effect) on multiple markers of inflammation in the absence of interferon-gamma (IFN-γ) co-stimulation. Nevertheless, initial experiments on clonal macrophages discovered that equimolar and physiological levels of D-lactate increased Nos2 expression compared to L-lactate. Bone marrow-derived macrophages (BMDMs) co-stimulated with IFN-γ revealed a larger effect of D-lactate on immunity. Compared to L-lactate, D-lactate increased nitric oxide (NO) production and increased activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome in BMDMs co-stimulated with IFN-γ and exposed to LPS. Further, D-lactate prevented L-lactate-induced lowering of NO production and NLRP3 inflammasome-mediated release of IL-1β from BMDMs co-stimulated with IFN-γ and LPS. Identifying appropriate cell models and defining conditions that reveal the effect of D-lactate versus L-lactate on immune responses in isolated cells was a major contribution of this work. Future work should characterize the interaction of macrophages and hepatocytes. This research may lead to the identification of gut microbiota-based approaches to limit liver inflammation in obesity and metabolic disease.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Gut bacteria can influence both immunity and metabolism in the liver. It is not clear how bacteria in the gut communicate to the liver. Lactate is a key metabolite that can fuel liver metabolism and alter immunity. There are 2 types of lactate. L-lactate is host-derived, whereas D-lactate is mainly produced by gut bacteria. Bacterial-derived D-lactate can alter immune responses mediated by immune cells in the liver, including macrophages. Bacterial metabolites such as D-lactate and bacterial components that cause inflammation are increased in the blood during obesity. Our findings show that D-lactate can increase inflammation in macrophages when combined with bacterial components and that D-lactate&#xd;
increases inflammation more than L-lactate. Understanding the role of D-lactate may help us understand how bacteria contribute to insulin resistance, higher blood glucose and the risk of type 2 diabetes and fatty liver disease.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Microbiota-derived D-lactate alters macrophage inflammation</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>